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Abstract
Background: Pleural angiosarcoma is a rare tumor that causes diffuse pleural thickening and effusion, mimicking
mesothelioma. Immunohistochemistry is needed to highlight endothelial differentiation. We describe the first case
of pleural angiosarcoma with lymphatic differentiation following radiometabolic therapy for thyroid carcinoma.
Case presentation: A 50-year-old man showed diffuse pleural thickening and effusion. Nine years earlier, he underwent
thyroidectomy and radiometabolic therapy for thyroid carcinoma with lymph node metastases. Histologically, the tumor
consisted of a solid proliferation of atypical epithelioid cells and anastomosed vascular spaces, lacking of red blood cells
and containing Alcian blue positive material. The tumor showed positive immunostaining for Vimentin, CD31, CK7,
D2–40, c-MYC, Ki67, focal positivity for PanCK, and negative immunostaining for Factor VIII, CD34, WT1, CK5/6, Calretinin,
EMA, HBME-1, CEA, p63, EpCAM, Bcl-2, TTF1 and Thyroglobulin. CD99 showed a granular/paranuclear pattern of positivity.
The histological and immunohistochemical features were consistent with “pleural angiosarcoma with lymphatic
differentiation, epithelioid variant”.
Discussion and conclusions: Epithelioid angiosarcoma with lymphatic differentiation is very rare and aggressive.
Moreover, the positivity for c-MYC suggests the relationship with radiometabolic therapy. To our knowledge, this
is the first case of pleural c-MYC-positive angiosarcoma with lymphatic differentiation reported in the literature
and the first one arisen after radiometabolic therapy for thyroid carcinoma.
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Background
Angiosarcoma (AS) is a malignant neoplasm with endo-
thelial differentiation, accounting for approximately 1–2%
of all soft tissue sarcomas. Pleura represents an ex-
ceedingly rare site for AS, with about 50 cases reported
in the literature [1]. Patients almost always die from
the disease within months. The diagnosis of this rare
pleural tumor is challenging, mimicking mesothelioma,
pulmonary carcinoma, or metastatic adenocarcinoma,
due to non-specific clinical and radiologic findings and
to the positivity for epithelial markers, such as pan-
cytokeratins (PanCK) and CK7. Markers of endothelial
differentiation, such as CD31, CD34 and Factor VIII,
are particularly useful in the identification of these
tumors [2, 3].
Lymphangiosarcoma (LAS) is even rare. Both AS and
LAS typically arise about 10 years after axillary nodal
dissection or radiation therapy for breast cancer with
long-standing massive lymphedema [4] and have been
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reported in literature as Stewart-Treves Syndrome. LAS
has been also evidenced after chronic lymphedema of
lower leg [5]. In serous membranes, few cases of LAS
have been reported after therapeutic irradiation [6].
We describe a case of primary pleural epithelioid AS
with lymphatic differentiation, clinically and radiologically
suspected as mesothelioma, arisen 9 years after radiometa-
bolic therapy (RMT) for thyroid papillary carcinoma with
multiple lymph node metastases. To the best of our know-
ledge, only one case of pleural epithelioid LAS has been
previously reported [1]. It is noteworthy that this is the
first reported case of pleural epithelioid AS with lymphan-
gioendothelial differentiation arisen after RMT for thyroid
carcinoma.
Case report
A 50 year-old male patient with a history of dyspnea was
admitted to our hospital.
Past medical history
Nine years earlier, in another hospital, the patient under-
went total thyroidectomy for papillary carcinoma with
dissection of the back-left jugular lymph nodes, one of
which metastatic.
The tumor was located in the upper half of the left
lobe and had a maximum diameter of 4,5 cm. The histo-
logic examination revealed a well differentiated papillary
carcinoma, classical variant, with multiple microscopic
foci in both lobes of the thyroid gland; the tumor stained
positively for TTF1 and Thyroglobulin. One out of 8
lymph nodes was metastatic.
After six months, PET and total body scintigraphy evi-
denced the presence of lymph node metastases on the
left side of the neck (level III and IV), and the patient
underwent RMT with iodine-131 (131I, 100 mCi).
Subsequently, he was subjected to surgical lymphad-
enectomy of 22 cervical and supraclavicular lymph
nodes, three of which metastatic. Due to the persist-
ence of residual lymph node metastases, he underwent
three cycles of RMT (100 mCi; 3,7GBq orally). So, he
received a cumulative dose of 400 mCi. It is note-
worthy that before the third cycle of RMT, the total
body scintigraphy evidenced low and widespread 131I
uptake in both lungs and in the para-medial left medi-
astinal area, leading to the suspicion of mediastinal
and lung involvement. Thoracic PET and CT did not
evidence nodular lesions, ruling out the suspicion of
metastasis.
Finally, a new lymphadenectomy was performed, due
to the persistence of metastases in 2/4 retro-clavear
lymph nodes, in 4/22 level II left lymph nodes and in
level III left lymph nodes.
Current medical history
The chest x-ray showed an opaque left hemithorax,
saving a small central lung area with contralateral
cardio-mediastinal shift [Fig. 1]. CT images showed ir-
regular circumferential pleural thickening with nodular
soft tissue masses involving the mediastinal and dia-
phragmatic pleura, extending into the fissures and redu-
cing the volume of the right lung. These features
clinically suggested pleural mesothelioma, and multiple
biopsies of the left parietal pleura were performed during
Video-Assisted Thoracotomy (VATS).
On microscopic examination, the hematoxylin-eosin
(H-E) sections of formalin-fixed paraffin-embedded bi-
opsies showed a neoplastic proliferation of highly atyp-
ical epithelioid cells with mitoses and areas of necrosis.
The tumor was composed of solid areas [Fig. 2a, b] and
“vasoformative” areas with variably sized anastomotic
vascular spaces, lined by atypical endothelial cells with
plump and prominent nuclei. Most of the vascular
spaces were lacking of red blood cells and contained cer-
tain amounts of Alcian blue positive material [Fig. 2c, d].
The immunohistochemical analysis showed positive im-
munostaining for Vimentin, CK7, D2–40 and focally for
PanCK [Fig. 3a-d], both in the vascular and in the solid
areas. The vascular endothelial lining showed focal posi-
tivity for CD31 [Fig. 4a].CD34, Factor VIII related-
antigenand WT1 stained positively only in a few non-
neoplastic vascular channels that were used as positive
internal control [Fig. 4b-d]. CD99 showed a paranuclear
pattern and/or granular pattern of positivity [Fig. 4e].
Nuclei of many tumor cells stained positively for c-MYC
[Fig. 4f]. Calretinin, CK5/6, EMA, HBME-1, TTF-1,
Thyroglobulin and CEA stained negatively [Fig. 5a-g].
The expression of Ki67 was high, with about 30% of
positive neoplastic nuclei [Fig. 5h]. Finally, negative im-
munostaining was evidenced for p63, Bcl-2, EpCAM and
LNA-1 HHV8. The overall morphologic and immuno-
histochemical features supported the diagnosis of pleural
malignant epithelioid vascular tumor, consistent with
epithelioid AS with lymphatic differentiation.
Discussion
Pleural AS is a rare malignant neoplasm composed of
atypical and pleomorphic endothelial cells lining abnor-
mal vascular spaces. The radiologic features are nonspe-
cific and usually show unilateral or bilateral effusion and
diffuse pleural thickening that can easily simulate meso-
thelioma or metastases. Mass lesions are seen in about
half of the patients [2, 3]. There are two histological
variants of pulmonary/pleural AS: classical and epitheli-
oid. Classical AS exhibits a “vasoformative” pattern, with
irregular anastomotic vascular spaces containing red blood
cells, lined by atypical endothelial cells. “Vasoformative”
component is focal in epithelioid AS, that instead shows a
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predominant solid growth pattern composed of large,
round to polygonal epithelioid cells with abundant eosino-
philic cytoplasm, large pleomorphic nuclei and prominent
nucleoli. Epithelioid features are mentioned in the majority
of pleural AS (72,5%) and constitute a variable proportion
of the tumors [2, 7].
Immunohistochemical staining play an important role
in the differential diagnosis. Our case consisted of both
solid epithelioid areas and anastomosing vascular areas. It
showed co-expression of Vimentin, CK7, D2–40, focal
PanCK, but it stained negatively for EMA, CEA, EpCAM,
usually positive in sarcomatoid carcinoma. The negative
Fig. 1 CT image revealed irregular circumferential pleural thickening with nodular soft tissue masses, involving the mediastinal and diaphragmatic
pleura, and extending into the fissures, with reduction of right lung volume
Fig. 2 a On low power magnification, the tumor consisted of “vasoformative” areas admixed with more solid areas. b Solid areas constituted by
highly atypical epithelioid cells. c “Vasoformative” areas characterized by vascular channels lined by plumped atypical cells, lacking of red blood
cells. d Vascular channels containing Alcianblue positive mucoid substance. a: 40×, H-E; b: 200×, H-E; c: 100×, H-E; d: Alcian-PAS, 200×
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immunostaining for EMA and for markers usually positive
in mesothelioma, such asCK5/6, Calretinin, HBME1, to-
gether with the positive immunostaining for CD31, were
useful in the differential diagnosis with mesothelioma.
CD31 in fact is a marker of vascular lineage, more sensible
and specific than CD34, WT1, FVIII, and it is almost al-
ways negative in non-vascular neoplasms, such as meso-
theliomas and carcinomas [3, 8, 9].
Among the vascular neoplasias, the differential diagnosis
between angiosarcoma and epithelioid hemangioendothe-
lioma can be very challenging. Epithelioid hemangioen-
dothelioma typically arises from blood vessels with a
characteristic appearance at low-power magnification and
it is composed of short strands or solid nests of epithelioid
endothelial cells. Distinct vascular spaces are rarely ob-
served and more frequently the tumor cells form small
Fig. 3 Positive immunostaining for Vimentin (a), CK7 (b), D2–40 (c) Focal positive immunostaining for PanCK (d). a-d: 200×, immunoperoxidase stain
Fig. 4 a Positive immunostaining for CD31. b-c Negative immunostaining for CD34 (b) FVIII (c) and WT1 (d). A few non-neoplastic positive
vascular spaces have been used as internal positive control. e Vacuolar/paranuclear positive pattern of CD99. f Positive nuclear immunostaining
for c-MYC. a-f: 200×, immunoperoxidase stain
Cabibi et al. Diagnostic Pathology  (2017) 12:60 Page 4 of 7
intracellular lumens. Conversely, epithelioid angiosarco-
mas are composed of solid sheets of highly atypical, mitot-
ically active epithelioid cells of endothelial lineage.
Necrosis is common, and vascular differentiation is evi-
denced by the formation of irregular sinusoidal vascular
channels in the “vasoformative” areas [10].
Some authors reported that grade 3 AS could co-
express both blood and lymphatic markers [11]. On the
other side, Kahn et al. stated that D2–40 stains all be-
nign lymphatic tumors but not benign proliferations of
blood vessel origin. So, they concluded that “a subset of
AS with positive D2-40 cells can bear partial differenti-
ation along the lymphatic endothelial lineage and should
be classified as LAS” [12].
In our case, the presence of sinusoidal vascular channels
lacking of red blood cells and containing amorphous
Alcian blue positive substance, the marked cellular atypia,
the presence of necrosis and numerous atypical mitoses,
the high Ki67 expression and the positive immunostaining
for CD31 and D2–40 were more consistent with the
diagnosis of “epithelioid angiosarcoma with lymphatic
differentiation”.
Finally, for both the morphological and immunohis-
tochemical features it is worth noting the negative
immunostaining for TTF1 and thyroglobulin. This makes
unlikely to assume metastasis from the well differenti-
ated papillary carcinoma, that stained positively for
TTF1 and thyroglobulin and surgically removed nine
years earlier. Although the expression of CD99 has
been reported in several malignant neoplasias and it
is not specific, the focal expression of CD99 was in
keeping with previous studies highlighting CD99
staining in 25% of the epithelioid sarcomas [13].
AS represents a well-known complication in the set-
ting of chronic lymphedema (Stewart-Treves Syndrome)
and after radiotherapy for breast carcinoma, carcinoma
of the vulva and Hodgkin lymphoma [14–16]. Primary
pleural AS is very rare and the pathogenesis is still
unknown. Recently, Zhang et al. described a case of “de
novo pleural epithelioid AS” and they found only 18
cases of primary AS of the pleura previously reported in
the literature [17].
Some case reports from Japan indicate the relationship
with chronic tuberculous pyothorax [18, 19]. A history
of exposure to radiation or asbestos was noted in a few
Western cases [3]. Our patient was repeatedly subjected
to lymphadenectomy but he never showed signs of
lymphatic stasis. It is noteworthy that during the treat-
ment, a total-body scintigraphy evidenced a low and
widespread uptake of 131I in both lungs and in the para-
medial left mediastinal area.
Moreover, the positivity for c-MYC is in keeping with
recent studies reporting that positive nuclear immuno-
staining for c-MYC “can reliably discriminate between
Fig. 5 Negative immunostaining for Calretinin (a), CK5/6 (b), EMA (c), HBME-1 (d) TTF-1 (e), Thyroglobulin (f), CEA (g). Positive nuclear immunostaining
for Ki67 (h). a-h: 200×, immunoperoxidase stain
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AS secondary to irradiation and AS arising de novo, that
are morphologically indistinguishable” [20–23].
Previous studies suggested that the exposure to ioni-
zing radiation from radioisotope therapy or external
local radiotherapy raises the risk of developing second
primary cancers, and the risk increases with cumula-
tive doses of 131I [24–29]. Our patient received a 131I
cumulative dose of 400 mCi and he died four months
after the diagnosis.
Conclusions
In this case of c-MYC positive pleural angiosarcoma
with lymphatic differentiation, a pathogenetic relation-
ship between the pleural AS and the oncogenic effects of
the ionizing radiations could be hypothesized. To the
best of our knowledge, this is the first case of pleural AS
with lymphatic differentiation following radiometabolic
exposure for metastatic thyroid papillary carcinoma and
the first pleural AS with lymphatic differentiation in
which c-MYC positivity has been highlighted.
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